OpenURL Connection Search

Select item for more details and to access through your institution.

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Published in:
Journal of Cancer Research & Clinical Oncology, 2014, v. 140, n. 2, p. 221, doi. 10.1007/s00432-013-1556-4
By:
- Gamucci, T.;
- Moscetti, L.;
- Mentuccia, L.;
- Pizzuti, L.;
- Mauri, M.;
- Zampa, G.;
- Pavese, I.;
- Sperduti, I.;
- Vaccaro, A.;
- Vici, P.
Publication type:
Article
Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.
Published in:
Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 5, p. 853, doi. 10.1007/s00432-013-1388-2
By:
- Gamucci, T.;
- Vaccaro, A.;
- Ciancola, F.;
- Pizzuti, L.;
- Sperduti, I.;
- Moscetti, L.;
- Longo, F.;
- Fabbri, M.;
- Giampaolo, M.;
- Mentuccia, L.;
- Di Lauro, L.;
- Vici, P.
Publication type:
Article
Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations.
Published in:
2011
By:
- Farina G;
- Longo F;
- Martelli O;
- Pavese I;
- Mancuso A;
- Moscetti L;
- Labianca R;
- Bertolini A;
- Cortesi E;
- Farris A;
- Fagnani D;
- Locatelli MC;
- Valmadre G;
- Ardizzoia A;
- Tomirotti M;
- Rulli E;
- Garassino MC;
- Scanni A
Publication type:
Journal Article
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Published in:
2012
By:
- Grossi F;
- de Marinis F;
- Gebbia V;
- Riccardi F;
- Caffo O;
- Gamucci T;
- Ferraù F;
- Nardi M;
- Moscetti L;
- Boni L;
- Dondi D;
- Galligioni E
Publication type:
Journal Article
Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.
Published in:
2007
By:
- Gamucci, T.;
- D'Ottavio, A. M.;
- Magnolfi, E.;
- Barduagni, M.;
- Vaccaro, A.;
- Sperduti, I.;
- Moscetti, L.;
- Belli, F.;
- Meliffi, L.
Publication type:
journal article
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Published in:
2005
By:
- Di Costanzo, F.;
- Carlini, P.;
- Doni, L.;
- Massidda, B.;
- Mattioli, R.;
- Iop, A.;
- Barletta, E.;
- Moscetti, L.;
- Recchia, F.;
- Tralongo, P.;
- Gasperoni, S.
Publication type:
journal article

Found: 6

Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.

Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis.

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations.

A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer.

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).